{
    "id": 2158,
    "fullName": "MET act mut",
    "impact": "unknown",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MET act mut indicates that this variant results in a gain of function in the Met protein. However, the specific amino acid change has not been identified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 4233,
        "geneSymbol": "MET",
        "terms": [
            "MET",
            "AUTS9",
            "c-Met",
            "DFNB97",
            "HGFR",
            "RCCP2"
        ]
    },
    "variant": "act mut",
    "createDate": "10/09/2014",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11440,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Savolitinib (AZD6094) resulted in an overall response rate (ORR) of 18% (8/44, all partial responses) in the subgroup of patients with MET-driven papillary renal cell carcinoma (PRCC), which included patients with MET kinase domain mutations, compared to an ORR of 0% (0/46) in patients with MET-independent PRCC (PMID: 28644771; NCT02127710).",
            "molecularProfile": {
                "id": 2096,
                "profileName": "MET act mut"
            },
            "therapy": {
                "id": 2161,
                "therapyName": "Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4465,
                "name": "papillary renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9389,
                    "pubMedId": 28644771,
                    "title": "Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28644771"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1770,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, S-49076 inhibited Met activation, resulting in growth inhibition of gastric carcinoma cells harboring MET activating mutations in culture and in cell line xenograft models (PMID: 23804704).",
            "molecularProfile": {
                "id": 2096,
                "profileName": "MET act mut"
            },
            "therapy": {
                "id": 2158,
                "therapyName": "S-49076",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2007,
                    "pubMedId": 23804704,
                    "title": "S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23804704"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9538,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells harboring MET activating mutations demonstrated sensitivity to treatment with Glesatinib (MGCD265) in cell-based assays (AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3609).",
            "molecularProfile": {
                "id": 2096,
                "profileName": "MET act mut"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7264,
                    "pubMedId": null,
                    "title": "Abstract 3609: MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in Phase II clinical development, potently inhibits clinically relevant Met mutants",
                    "url": "http://cancerres.aacrjournals.org/content/70/8_Supplement/3609.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1757,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BMS-777607 (ASLAN002) demonstrated efficacy in blocking Met phosphorylation and inhibiting cell proliferation and metastasis in cultured cells and murine models with activating Met mutations (PMID: 22286523).",
            "molecularProfile": {
                "id": 2096,
                "profileName": "MET act mut"
            },
            "therapy": {
                "id": 687,
                "therapyName": "BMS-777607",
                "synonyms": null
            },
            "indication": {
                "id": 1115,
                "name": "sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2026,
                    "pubMedId": 22286523,
                    "title": "Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22286523"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3792,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tepotinib (MSC2156119J) inhibited tumor growth in hepatocellular cancer (HCC) mouse xenograft models with MET overexpression or activation (Cancer Res April 15, 2013; 73(8 Supplement): 925)",
            "molecularProfile": {
                "id": 2096,
                "profileName": "MET act mut"
            },
            "therapy": {
                "id": 1398,
                "therapyName": "Tepotinib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 529,
                    "pubMedId": null,
                    "title": "Abstract 925: The c-Met inhibitor MSC2156119J effectively inhibits growth of liver cancer models.",
                    "url": null
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9980,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Merestinib (LY2801653) demonstrated anti-tumor activity in cell line xenograft models of glioma with autocrine activation of Met signaling (PMID: 23275061).",
            "molecularProfile": {
                "id": 2096,
                "profileName": "MET act mut"
            },
            "therapy": {
                "id": 1030,
                "therapyName": "Merestinib",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 331,
                    "pubMedId": 23275061,
                    "title": "LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23275061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9535,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Altiratinib (DCC-2701) inhibited MET activity, including MET activating mutations, and inhibited proliferation of MET-driven tumor cell lines in culture (PMID: 26285778).",
            "molecularProfile": {
                "id": 2096,
                "profileName": "MET act mut"
            },
            "therapy": {
                "id": 1656,
                "therapyName": "Altiratinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7263,
                    "pubMedId": 26285778,
                    "title": "Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26285778"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1696,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Emibetuzumab (LY2875358) treatment inhibited MET activation and proliferation of tumor cells with constitutive MET activation in culture, and inhibited tumor growth in xenograft models (PMID: 25231402).",
            "molecularProfile": {
                "id": 2096,
                "profileName": "MET act mut"
            },
            "therapy": {
                "id": 803,
                "therapyName": "Emibetuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1762,
                    "pubMedId": 25231402,
                    "title": "LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25231402"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6822,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Xalkori (crizotinib) was generally well-tolerated and demonstrated preliminary efficacy in patients with non-small cell lung cancer harboring MET exon 14 alterations, with anti-tumor activity demonstrated in 10/15 evaluable patients (J Clin Oncol 34, 2016 (suppl; abstr 108)).",
            "molecularProfile": {
                "id": 2096,
                "profileName": "MET act mut"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5837,
                    "pubMedId": null,
                    "title": "Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC).",
                    "url": "http://abstracts.asco.org/176/AbstView_176_167889.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14154,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion and with transposon insertions in YES1, leading to increased expression and phosphorylation of Yes1, demonstrated sensitivity to the combination of Tagrisso (osimertinib) and Saracatinib (AZD0530) in culture, resulting in decreased Akt and Erk phosphorylation and reduced cell viability (PMID: 29875142).",
            "molecularProfile": {
                "id": 29950,
                "profileName": "EGFR exon 19 del MET act mut"
            },
            "therapy": {
                "id": 7029,
                "therapyName": "Osimertinib + Saracatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14149,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transposon insertions in MET, leading to increased phosphorylation of Met, were associated with resistance to Tagrisso (osimertinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).",
            "molecularProfile": {
                "id": 29950,
                "profileName": "EGFR exon 19 del MET act mut"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14148,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transposon insertions in MET, leading to increased phosphorylation of Met, were associated with resistance to Gilotrif (afatinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).",
            "molecularProfile": {
                "id": 29950,
                "profileName": "EGFR exon 19 del MET act mut"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14150,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion and with transposon insertions in MET, leading to increased Met phosphorylation, demonstrated sensitivity to the combination of Gilotrif (afatinib) and Xalkori (crizotinib) in culture, resulting in decreased Akt and Erk phosphorylation and reduced cell viability (PMID: 29875142).",
            "molecularProfile": {
                "id": 29950,
                "profileName": "EGFR exon 19 del MET act mut"
            },
            "therapy": {
                "id": 3378,
                "therapyName": "Afatinib + Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14145,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transposon insertions in MET, leading to increased expression and phosphorylation of Met, were associated with resistance to Tarceva (erlotinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).",
            "molecularProfile": {
                "id": 29950,
                "profileName": "EGFR exon 19 del MET act mut"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2096,
            "profileName": "MET act mut",
            "profileTreatmentApproaches": [
                {
                    "id": 476,
                    "name": "MET Inhibitor",
                    "profileName": "MET act mut"
                }
            ]
        },
        {
            "id": 29950,
            "profileName": "EGFR exon 19 del MET act mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}